Nat Commun:强迫症背后有哪些基因变异在操控

2017-10-19 佚名 “Nature自然科研”微信号

本周《自然-通讯》在线发表的一篇文章Integrating evolutionary and regulatory information with a multispecies approach implicates genes and pathways in obsessive-compulsive disorder鉴别了与强迫症(OCD)相关的人类基因变异。研究人员找到了受这些变异影响的基因

本周《自然-通讯》在线发表的一篇文章Integrating evolutionary and regulatory information with a multispecies approach implicates genes and pathways in obsessive-compulsive disorder鉴别了与强迫症(OCD)相关的人类基因变异。研究人员找到了受这些变异影响的基因及神经通路。分离和表征这些基因或许能帮助我们理解这种疾病背后的生物学,并建立治疗方案。

OCD有很强的遗传性,这种衰竭性神经精神疾病的主要表现为侵入性思维和浪费时间的重复行为。全球超过8千万人患有OCD,其中大部分都无法从现有的治疗中得到解脱。此前对人类、小鼠和犬的研究也指出一些可能与OCD相关的变异,但是确切的基因和变异并未能在人类中确定。

通过分析608个候选基因的测序数据,美国哈佛-麻省理工博德研究所的Hyun Ji Noh及同事在人类案例中鉴定出4个与OCD关联紧密的基因。这些基因在与OCD关联的神经通路中作用,包括血清素和谷氨酸盐信号传递及突触联系——它们可能是潜在的药物作用靶点。这些发现提供了对强迫性行为的生物学基础的新认识。


四大候选基因(红色表示)在突触中起作用,并与OCD相关的蛋白质相互作用。实线表示直接作用,虚线表示间接作用。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1882548, encodeId=c5c31882548e0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Dec 04 04:40:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087166, encodeId=784e208e166d8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Oct 02 07:40:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314160, encodeId=47c613141606a, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sat Oct 21 04:40:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342436, encodeId=3a831342436bc, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Oct 21 04:40:00 CST 2017, time=2017-10-21, status=1, ipAttribution=)]
    2017-12-04 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1882548, encodeId=c5c31882548e0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Dec 04 04:40:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087166, encodeId=784e208e166d8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Oct 02 07:40:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314160, encodeId=47c613141606a, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sat Oct 21 04:40:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342436, encodeId=3a831342436bc, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Oct 21 04:40:00 CST 2017, time=2017-10-21, status=1, ipAttribution=)]
    2018-10-02 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1882548, encodeId=c5c31882548e0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Dec 04 04:40:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087166, encodeId=784e208e166d8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Oct 02 07:40:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314160, encodeId=47c613141606a, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sat Oct 21 04:40:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342436, encodeId=3a831342436bc, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Oct 21 04:40:00 CST 2017, time=2017-10-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1882548, encodeId=c5c31882548e0, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Dec 04 04:40:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087166, encodeId=784e208e166d8, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Oct 02 07:40:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314160, encodeId=47c613141606a, content=<a href='/topic/show?id=b5e641e1279' target=_blank style='color:#2F92EE;'>#基因变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41712, encryptionId=b5e641e1279, topicName=基因变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sat Oct 21 04:40:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342436, encodeId=3a831342436bc, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Oct 21 04:40:00 CST 2017, time=2017-10-21, status=1, ipAttribution=)]

相关资讯

中国强迫症防治指南2016(精编版)

为了帮助临床医生提高强迫症的诊疗技能,自2014年开始,经中华医学会精神医学分会常委会批准,成立了《中国强迫症防治指南》(简称为《指南》)编写组,历经2年多完成了《指南》编写,最终由中华医学会精神医学分会常委会批准发布。 《指南》的读者主要为临床一线工作的精神卫生从业人员,包括精神科专科医师、全科医师、综合医院心理(心身)科及其他各科医师、精神科护理人员、临床社工师以及精神卫生管理人员。

Transl Psychiatry:研究发现:“认知行为疗法”强迫症患者的希望

研究人员在接受了一种认知行为疗法后,用脑部扫描来测量强迫症患者大脑活动的变化。他们发现,关键大脑网络的连接性得到了改善,这表明了这种治疗具有可行性。

美国精神病学会认定:“自拍成瘾”是精神疾病!

“眉梢斜上方45度的最佳角度,窗子或者镜子反射的光线最理想,构思一个完美的姿势,然后按下拍摄键。

强迫症?得吃药

生活中充满选择,有时你很难弄清选择是否正确。不过,一种能阻止人体内去甲肾上腺素激增的药物,或许能增强你的自信,并有望带来精神分裂症和强迫症的新疗法。

中国强迫症防治指南2016 解读:概述

中华医学会精神医学分会组织专家编写了《中国强迫症防治指南》。考虑到DSM-5中新纳入的躯体变形障碍、拔毛症、囤积障碍和抓痕障碍并未获得广泛认可且相关研究较少,所以《指南》中仅涉及强迫症的相关内容。该《指南》是中华医学会精神医学分会系列疾病防治指南之一,总体上遵循了系列指南的统一原则和风格,突出了诊疗,根据不同的临床特征提出相应的治疗建议;强调了科学性,注重循证证据,尽可能全面检索强迫症相关的国内外

Nature Commun:强迫症与基因变异有关系

东西一定要放得整整齐齐,出门时要检查好几次有没有上锁……相信每个人的身边都有这样的朋友。我们一般管这种行为叫做“强迫症”。据估计,全世界有超过8000万人受强迫症的影响,其中许多人会产生不自主的强迫性思考,做上一些外人难以理解的重复行为。